Abstract: A method for starting a wind turbine with hinged wind turbine blades, the wind turbine further comprising an adjustable biasing mechanism arranged to apply an adjustable biasing force to each wind turbine blade which biases the wind turbine blade towards a position defining a minimum pivot angle. The biasing mechanism is adjusted to apply a predefined biasing force to each wind turbine blade, and the pivot angle of each wind turbine blade is monitored. The wind turbine is started in the case that the pivot angle of at least one wind turbine blade exceeds a predefined pivot angle threshold.

Abstract: A system and method for simulating injury treatment on a living body are provided. The system includes an embedded system configured to be placed on a living body and to simulate an injury of the living body in response to instructions received from a simulation system. Sensors detect a parameter corresponding to a treatment of said injury and transmit said parameter to said simulation system which transmit the instructions to the embedded system to cause it to simulate the injury. The simulation system is further configured to receive sensor data representing the parameter detected by the sensors and the treatment of the injury, and to execute a simulation scenario, which associates the detected parameter with a corresponding effect on the injury. Furthermore, the simulation system is configured to send instructions to the embedded system, which cause the embedded system to simulate the injury such that the simulation reflects the treatment.

Abstract: A system and method for simulating injury treatment on a living body are provided. The system includes an embedded system configured to be placed on a living body and to simulate an injury of the living body in response to instructions received from a simulation system. Sensors detect a parameter corresponding to a treatment of said injury and transmit said parameter to said simulation system which transmit the instructions to the embedded system to cause it to simulate the injury. The simulation system is further configured to receive sensor data representing the parameter detected by the sensors and the treatment of the injury, and to execute a simulation scenario, which associates the detected parameter with a corresponding effect on the injury. Furthermore, the simulation system is configured to send instructions to the embedded system, which cause the embedded system to simulate the injury such that the simulation reflects the treatment.

Abstract: The invention relates to a porous hydrogel matrix having substantially interconnected tunnel-shaped micropores with a three-dimensional configuration of an interconnected hollow tetrapod network. Such matrices may be used to entrap motile cells that migrate into the micropores of said matrix. The matrices of the invention are formed by a method comprising the steps of providing a solution of a hydrogel-forming material, providing a template material with a three-dimensional configuration corresponding to the negative configuration of the desired interconnected porous structure of the hydrogel material, said template material comprising interconnected zinc oxide tetrapod (t-ZnO) networks, casting the solution of hydrogel-forming material onto the template and removing the template material from the hydrogel material by acid hydrolysis of the template material.

Abstract: The invention relates to a porous hydrogel matrix having substantially interconnected tunnel-shaped micropores with a three-dimensional configuration of an interconnected hollow tetrapod network. Such matrices may be used to entrap motile cells that migrate into the micropores of said matrix. The matrices of the invention are formed by a method comprising the steps of providing a solution of a hydrogel-forming material, providing a template material with a three-dimensional configuration corresponding to the negative configuration of the desired interconnected porous structure of the hydrogel material, said template material comprising interconnected zinc oxide tetrapod (t-ZnO) networks, casting the solution of hydrogel-forming material onto the template and removing the template material from the hydrogel material by acid hydrolysis of the template material.

Abstract: The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.

Abstract: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Abstract: The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Abstract: The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.

Abstract: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Abstract: The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces a HBP which binds to a HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising administering to said mammal a HBP antagonist in an amount effective to decrease the release of bradykinin in a mammal. Furthermore, the invention is directed to methods and kits for determining if a mammal produces HBP that binds to a HBP antagonist, e.g., a monoclonal antibody that binds to at least one epitope of human HBP and a method for detecting an antagonist of HBP.

Abstract: Analogs of GLP-2, pharmaceutical compositions comprising GLP-2 analogs, and methods of treating diseases and disorders comprising administering such analogs or compositions are provided.

Abstract: The invention concerns a preparation comprising a plurality of Factor VII polypeptides or Factor VII-related polypeptides, wherein the polypeptides comprise asparagine-linked and/or serine-linked oligosaccharide chains, and wherein at least one oligosaccharide group is covalently attached to at least one polymeric group.

Abstract: The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.

Abstract: The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.

Abstract: The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

Abstract: The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces a HBP which binds to a HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising administering to said mammal a HBP antagonist in an amount effective to decrease the release of bradykinin in a mammal. Furthermore, the invention is directed to methods and kits for determining if a mammal produces HBP that binds to a HBP antagonist, e.g., a monoclonal antibody that binds to at least one epitope of human HBP and a method for detecting an antagonist of HBP.

Abstract: A parenterally administrable, biodegradable microparticle preparation containing a biologically active substance which, during the first 24 hours after injection, exhibits a release of the active substance that is less than 25% of the total release, determined from a concentration-time curve in the form of the ratio between the area under the curve during the said first 24 hours and the total area under the curve in question

Abstract: The present invention relates to novel compounds that bind to and inhibit the activity of tissue factor (TF) and mediate a cytolytic immune response.